CKD
MCID: CHR684
MIFTS: 70

Chronic Kidney Disease (CKD)

Categories: Blood diseases, Bone diseases, Genetic diseases, Nephrological diseases

Aliases & Classifications for Chronic Kidney Disease

MalaCards integrated aliases for Chronic Kidney Disease:

Name: Chronic Kidney Disease 12 29 6 42 3 15 37 62 17 32
Chronic Renal Disease 12 15
Ckd 12 3
Chronic Renal Failure Syndrome 12
Renal Failure - Chronic 12
Kidney Failure, Chronic 43
Chronic Kidney Failure 12
Chronic Renal Failure 74
Renal Failure Chronic 54
Crf 12

Classifications:



External Ids:

Disease Ontology 12 DOID:784
ICD9CM 34 585
MeSH 43 D007676
NCIt 49 C9438
SNOMED-CT 67 46177005
ICD10 32 N18 N18.9
UMLS 71 C0022661

Summaries for Chronic Kidney Disease

MedlinePlus : 42 You have two kidneys, each about the size of your fist. Their main job is to filter your blood. They remove wastes and extra water, which become urine. They also keep the body's chemicals balanced, help control blood pressure, and make hormones. Chronic kidney disease (CKD) means that your kidneys are damaged and can't filter blood as they should. This damage can cause wastes to build up in your body. It can also cause other problems that can harm your health. Diabetes and high blood pressure are the most common causes of CKD. The kidney damage occurs slowly over many years. Many people don't have any symptoms until their kidney disease is very advanced. Blood and urine tests are the only way to know if you have kidney disease. Treatments cannot cure kidney disease, but they may slow kidney disease. They include medicines to lower blood pressure, control blood sugar, and lower cholesterol. CKD may still get worse over time. Sometimes it can lead to kidney failure. If your kidneys fail, you will need dialysis or a kidney transplantation. You can take steps to keep your kidneys healthier longer: Choose foods with less salt (sodium) Control your blood pressure; your health care provider can tell you what your blood pressure should be Keep your blood sugar in the target range, if you have diabetes Limit the amount of alcohol you drink Choose foods that are healthy for your heart: fruits, vegetables, whole grains, and low-fat dairy foods Lose weight if you are overweight Be physically active Don't smoke NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Chronic Kidney Disease, also known as chronic renal disease, is related to renal osteodystrophy and kidney disease. An important gene associated with Chronic Kidney Disease is COL4A4 (Collagen Type IV Alpha 4 Chain), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Pathways in cancer. The drugs Nitric Oxide and Nifedipine have been mentioned in the context of this disorder. Affiliated tissues include Bone and Adipose, and related phenotypes are cardiovascular system and homeostasis/metabolism

Disease Ontology : 12 A kidney failure that is characterized by the gradual loss of kidney function.

CDC : 3 CKD is a condition in which the kidneys are damaged and cannot filter blood as well as they should. Because of this, excess fluid and waste from blood remain in the body and may cause other health problems, such as heart disease and stroke.

PubMed Health : 62 About chronic kidney disease: Our kidneys are vital organs that clean our blood and affect many different bodily functions. Various medical conditions can cause the kidneys to stop working properly for a short time – for example, if blood isn’t pumped around the body properly or if an enlarged prostate or kidney stones make urine build up in the kidneys. But if the kidneys still aren’t working at full capacity more than three months later or are permanently damaged, then the problem is considered to be chronic kidney disease. The most common causes in adults are diabetes and high blood pressure. Older people are especially prone to developing chronic kidney disease. It often goes unnoticed for a long time because poorly functioning kidneys don’t cause any problems at first. Treatment mostly aims to stop the kidney disease from getting worse, or at least delay the process. It is also important to treat complications such as anemia, acidosis or changes in bone metabolism. If the kidneys fail completely, dialysis or a kidney transplant can prolong the person’s life.

Wikipedia : 74 Chronic kidney disease (CKD) is a type of kidney disease in which there is gradual loss of kidney... more...

Related Diseases for Chronic Kidney Disease

Diseases in the Kidney Disease family:

Acute Kidney Failure Renal Infectious Disease
Chronic Kidney Disease Ren-Related Kidney Disease

Diseases related to Chronic Kidney Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1520)
# Related Disease Score Top Affiliating Genes
1 renal osteodystrophy 34.5 PTH FGF23 EPO CASR
2 kidney disease 34.3 UMOD REN PTH PKD2 PKD1 NPHS2
3 end stage renal disease 34.3 UMOD REN PTH PKD2 PKD1 NPHS2
4 secondary hyperparathyroidism 34.0 PTH FGF23 EPO CASR ALB
5 microvascular complications of diabetes 3 33.7 REN INS ALB ACE
6 autosomal dominant tubulointerstitial kidney disease 33.6 UMOD REN
7 calciphylaxis 33.6 PTH FGF23 EPO CASR ALB
8 cystic kidney disease 33.5 UMOD REN PTH PKD2 PKD1 MKS1
9 hypokalemia 33.5 REN INS CASR ALB ACE
10 hypoparathyroidism 33.4 PTH INS FGF23 CASR
11 diabetes mellitus 33.1 UMOD TUG1 REN PTH INS FGF23
12 pierson syndrome 33.1 NPHS2 COL4A5 COL4A4
13 hyperparathyroidism 33.0 PTH FGF23 EPO CASR ALB
14 hypoparathyroidism, sensorineural deafness, and renal disease 32.9 PTH NPHS2 CASR
15 hyperphosphatemia 32.9 PTH FGF23 CRP CASR ALB
16 autosomal dominant tubulointerstitial kidney disease, ren-related 32.8 UMOD REN
17 deficiency anemia 32.8 PTH INS FGF23 EPO CRP ALB
18 lipid metabolism disorder 32.8 INS CRP APOA1 ACE
19 glomerulonephritis 32.7 NPHS2 COL4A5 COL4A4 COL4A3 ALB ACE
20 anemia, x-linked, with or without neutropenia and/or platelet abnormalities 32.7 EPO CRP ALB
21 uremia 32.7 REN PTH INS EPO CRP CASR
22 vascular disease 32.7 REN PTH INS EPO CST3 CRP
23 rickets 32.6 PTH FGF23 CASR ALB
24 congestive heart failure 32.6 REN INS EPO CRP ALB ACE
25 hyperuricemia 32.6 UMOD REN PTH INS CRP ALB
26 peripheral vascular disease 32.5 INS EPO CRP APOA1 ALB ACE
27 arteries, anomalies of 32.5 REN INS CRP APOA1 ALB ACE
28 lipoprotein quantitative trait locus 32.4 REN CRP APOA1 ALB ACE
29 heart disease 32.4 REN INS EPO CST3 CRP APOA1
30 atrial fibrillation 32.4 REN INS CRP ALB ACE
31 polycystic kidney disease 32.4 REN PKD2 PKD1 FGF23 EPO CST3
32 nephrotic syndrome 32.4 NPHS2 APOA1 ALB ACE
33 bone disease 32.3 PTH FGF23 EPO CASR
34 focal segmental glomerulosclerosis 32.3 NPHS2 COL4A5 COL4A4 COL4A3 ALB ACE
35 hypertension, essential 32.3 UMOD REN PTH PKD2 PKD1 NPHS2
36 osteoporosis 32.3 PTH INS FGF23 CST3 CRP CASR
37 sleep apnea 32.3 REN INS EPO CRP ALB ACE
38 acute kidney failure 32.2 UMOD REN CST3 ALB
39 iga glomerulonephritis 32.2 REN NPHS2 ALB ACE
40 nephrolithiasis 32.2 UMOD PTH INS FGF23 CASR ALB
41 arteriosclerosis 32.2 INS CST3 CRP APOA1 ACE
42 glomerular disease 32.2 NPHS2 ALB ACE
43 peripheral artery disease 32.2 CST3 CRP APOA1 ACE
44 hypercholesterolemia, familial, 1 32.2 INS CRP APOA1 ACE
45 coronary heart disease 1 32.2 INS CRP APOA1 ACE
46 bone resorption disease 32.2 PTH INS FGF23 CRP CASR ALB
47 hypothyroidism 32.2 REN INS CST3 CRP APOA1 ALB
48 cerebrovascular disease 32.2 REN INS CRP APOA1 ACE
49 acute cystitis 32.1 UMOD REN INS CST3 CRP ALB
50 autosomal dominant polycystic kidney disease 32.1 REN PKD2 PKD1 INS FGF23 CST3

Graphical network of the top 20 diseases related to Chronic Kidney Disease:



Diseases related to Chronic Kidney Disease

Symptoms & Phenotypes for Chronic Kidney Disease

MGI Mouse Phenotypes related to Chronic Kidney Disease:

45 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.42 ACE ALB APOA1 COL4A3 COL4A5 CRP
2 homeostasis/metabolism MP:0005376 10.28 ACE ALB APOA1 CASR COL4A3 COL4A4
3 cellular MP:0005384 10.26 ALB APOA1 CASR COL4A3 CST3 EPO
4 growth/size/body region MP:0005378 10.22 ACE CASR COL4A3 COL4A4 FGF23 INS
5 endocrine/exocrine gland MP:0005379 10.17 ACE ALB APOA1 CASR CST3 FGF23
6 immune system MP:0005387 10.16 ACE ALB CASR COL4A3 COL4A4 COL4A5
7 hematopoietic system MP:0005397 10.11 ACE CASR COL4A5 EPO FGF23 INS
8 digestive/alimentary MP:0005381 10.06 ALB CASR COL4A4 FGF23 INS MKS1
9 mortality/aging MP:0010768 9.86 ACE ALB CASR COL4A3 COL4A4 COL4A5
10 liver/biliary system MP:0005370 9.76 ACE ALB APOA1 EPO INS MKS1
11 renal/urinary system MP:0005367 9.47 ACE ALB CASR COL4A3 COL4A4 COL4A5

Drugs & Therapeutics for Chronic Kidney Disease

PubMed Health treatment related to Chronic Kidney Disease: 62

The most suitable treatment for chronic kidney disease will depend on the cause and stage of the disease, as well as on the person’s life circumstances and preferences. If the kidneys are still working at a nearly normal level, treatment should aim to stop or slow down the progression of the disease. This is mainly done using medication to lower blood pressure levels and prevent cardiovascular disease . If you have diabetes , it's important to regulate your blood sugar levels. If complications such as anemia or bone metabolism disorders have already occurred, then more medications are used – such as medicines that contain iron or stimulate the production of blood , as well as medications called “phosphate binders.” If there is too much acid in your body, bicarbonates are used. In addition to the medication, the treatment will include a diet suited to the stage of the disease, drinking the right amounts of liquids and physical exercise . Dialysis or a kidney transplant are considered if the kidneys fail completely. In the vast majority of people with complete kidney failure , at least one of these options is possible. Some people make a conscious decision not to use either, accepting the fact that they could die soon afterwards. Palliative treatment may then be suitable for them – enabling a final phase of life that is as pleasant as possible.

Drugs for Chronic Kidney Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 796)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nitric Oxide Approved Phase 4 10102-43-9 145068
2
Nifedipine Approved Phase 4 21829-25-4 4485
3
Peginterferon alfa-2b Approved Phase 4 99210-65-8, 215647-85-1
4
Fosinopril Approved Phase 4 98048-97-6 55891
5
Lithium carbonate Approved Phase 4 554-13-2
6
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
7
Enoxaparin Approved Phase 4 9005-49-6 772
8
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
9
Pitavastatin Approved Phase 4 147526-32-7, 147511-69-1 6366718 5282452
10
Digoxin Approved Phase 4 20830-75-5 30322 2724385
11
Scopolamine Approved, Investigational Phase 4 6533-68-2, 51-34-3 5184
12
Methyldopa Approved Phase 4 555-30-6 38853
13
Indapamide Approved Phase 4 26807-65-8 3702
14
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
15
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
16
Racepinephrine Approved Phase 4 329-65-7 838
17
Capsaicin Approved Phase 4 404-86-4 1548943
18
Darbepoetin alfa Approved, Investigational Phase 4 11096-26-7, 209810-58-2
19
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
20
Cinacalcet Approved Phase 4 226256-56-0 156419
21
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
22
Tinzaparin Approved Phase 4 9041-08-1, 9005-49-6 25244225
23
Dalteparin Approved Phase 4 9005-49-6
24
Lisinopril Approved, Investigational Phase 4 76547-98-3, 83915-83-7 5362119
25
Telavancin Approved Phase 4 372151-71-8
26
Zidovudine Approved Phase 4 30516-87-1 35370
27
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
28
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
29
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
30
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
31
Ramipril Approved Phase 4 87333-19-5 5362129
32
Deflazacort Approved, Investigational Phase 4 14484-47-0
33
Basiliximab Approved, Investigational Phase 4 152923-56-3, 179045-86-4
34
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
35
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
36
Amlodipine Approved Phase 4 88150-42-9 2162
37
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
38
Dolutegravir Approved Phase 4 1051375-16-6 54726191
39 Taurolidine Approved, Investigational Phase 4 19388-87-5
40
Terazosin Approved Phase 4 63590-64-7 5401
41
Alendronate Approved Phase 4 66376-36-1, 121268-17-5 2088
42
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
43
Linagliptin Approved Phase 4 668270-12-0 10096344
44
Colchicine Approved Phase 4 64-86-8 2833 6167
45
Iodine Approved, Investigational Phase 4 7553-56-2 807
46
Argatroban Approved, Investigational Phase 4 74863-84-6 152951
47
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
48
Bivalirudin Approved, Investigational Phase 4 128270-60-0 16129704
49
Amiloride Approved Phase 4 2016-88-8, 2609-46-3 16231
50
Regadenoson Approved, Investigational Phase 4 313348-27-5 219024

Interventional clinical trials:

(show top 50) (show all 4008)
# Name Status NCT ID Phase Drugs
1 Study on the Effect of Hyperuricaemia on Chronic Renal Disease and Intervention Unknown status NCT03425708 Phase 4 20mg Febuxostat;40mg Febuxostat
2 Evaluation of Nail Fold Microcirculation and Interventional Therapy in Patients With Chronic Renal Failure Unknown status NCT03682952 Phase 4 Alprostadil Injection;Beraprost sodium tablets
3 Effect of Hydration With Sodium Bicarbonate for Long-Term Clinical Outcomes in Patients With Chronic Kidney Disease Undergoing an Emergent Coronary Procedure Unknown status NCT00716001 Phase 4 N-acetylcysteine
4 Effects of an Exercise Program in Patients With Hypertensive Chronic Kidney Disease: a Randomized Clinical Trial Unknown status NCT01155128 Phase 4
5 Renoprotection by Combining Pentoxifylline and Angiotensin Blockade in Chronic Kidney Disease Unknown status NCT01377285 Phase 4 ARB;Pentoxifylline;Placebo (for Pentoxifylline)
6 Inspiratory Muscle Training in Patients With End Stage Renal Failure: a Randomized Controlled Trial Unknown status NCT01347775 Phase 4
7 A comParison on Platelet Resistance With Ticagrelor or Standard-Dose Clopidogrel Study Among SeVerE Chronic Kidney Disease/ End-Stage-Renal-Disease Patients With Recent Acute Coronary Syndrome. Unknown status NCT02459288 Phase 4 Clopidogrel first;Ticagrelor first
8 the Effect of Calcium Dobesilate on Non Dialysis Patients With Chronic Renal Failure Unknown status NCT03427944 Phase 4 Calcium Dobesilate group;Conventional Treatment group
9 Simvastatin Effect on Endothelium Dependent Venodilation in Chronic Renal Failure Patients Treated by Peritoneal Dialysis Unknown status NCT00291863 Phase 4 Simvastatin
10 NAC in Preventing CIN in CRF Patients Who Need Enhanced CT Scan in ED Unknown status NCT00501475 Phase 4 NAC Bicarbonate
11 Renal Toxicity of Iodixanol and Iopromide in Patients With Renal Dysfunction—a Multicentre, Single Blind, Randomized Controlled, Prospective Trial Unknown status NCT01580046 Phase 4 iodixanol;iopromide
12 The Effects of AST-120 on Endothelial Dysfunction in Patients With Chronic Kidney Disease Unknown status NCT01157260 Phase 4 Kremezin
13 Open Randomized Phase IV Study on Intravenous Iron in Anemic Patients With Chronic Kidney Disease Unknown status NCT00204256 Phase 4 Iron sucrose
14 Randomized, Open Label, Controlled Clinical Trial of Egg Albumin-Based Protein Supplement Versus Renal Specific Oral Supplement in Hemodialysis Patients Unknown status NCT01981083 Phase 4
15 Pulse Wave Velocity, Pulse Wave Morphology and Blocking of the Reninangiotensin System in Patients With Chronic Kidney Disease: An Interventional and Methodological Study Unknown status NCT00235287 Phase 4 Candesartan and enalapril;candesartan and enalapril;candesartan and enalapril;candesartan and enalapril
16 Providing Intravenous Paricalcitol Treatment to the Sick and Poor Chronic Hemodialysis Patients With Severe Secondary Hyperparathyroidism Resistant to Existing Vitamin D Analogs Unknown status NCT03023748 Phase 4 Intravenous Paricalcitol
17 Safety and Effect of Elbasvir/Grazoprevir Combination Therapy in Hemodialysis Patients With Chronic Hepatitis C Unknown status NCT03022006 Phase 4 elbasvir, grazoprevir
18 A Prospective, Randomized, Double Blind, Parallel Group Study to Establish the Therapeutic Equivalence of EPIAO® With the Standard Treatment EPREX® in Subjects With Chronic Kidney Disease (CKD) Related Anaemia Not Yet on Dialysis Unknown status NCT02522975 Phase 4 EPIAO®;EPREX®
19 Phase 4 Study of Alprostadil Prevent Contrast Induced Nephropathy in Patients Receiving a Cardiac Catheterization Unknown status NCT01722513 Phase 4 Alprostadil ﹠control
20 Effects of Cholecalciferol on Osteoprotegerin Levels and Other Clinical Outcomes in Chronic Kidney Disease Patients on Peritoneal Dialysis: a Randomized Controlled Trial Unknown status NCT02598635 Phase 4 Cholecalciferol;Placebo
21 Immunosuppression in Renal Transplantation in The Elderly: Time to Rethink. - nEverOld Study Unknown status NCT01631058 Phase 4 Everolimus
22 The Metabolic and Anti-Inflammatory Effects of Combined Ezetimibe and Simvastin Therapy, as Compared to Simvastatin Alone, in Patients With Chronic Proteinuric Nephropathy Unknown status NCT00861731 Phase 4 simvastatin;EZE/simvastatin;EZE/simvastatin
23 Hemocontrol's Effectiveness in a RAndomized Controlled Trial on the Reduction of Cardiovascular Long-term EventS Unknown status NCT01515878 Phase 4
24 Randomized Open Clinical Trial to Compare the Effectiveness of the Administration of Diuretics in Hemodialysis Patients With Residual Renal Function in Single Centre Unknown status NCT01977430 Phase 4 Hydrochlorothiazide and furosemide
25 Impact of a Mineralocorticoid Receptor Antagonist on Chronic Histological Changes in Renal Allograft Unknown status NCT01510795 Phase 4 spironolactone
26 The Impact of Conventional Hemodialysis, High Flux Hemodialysis and Hemodiafiltration on Adiponectin, Vascular Function and Clinical Prognosis Unknown status NCT00155363 Phase 4
27 Safety and Efficacy of Shenyankangfu Tablets for Chronic Kidney Disease Unknown status NCT02885857 Phase 4 Shenyan Kangfu Tablet
28 Effect of Valsartan vs Perindopril on HOMA-IR Index in Patients With Chronic Kidney Disease Unknown status NCT02299310 Phase 4 Valsartan;Perindopril
29 Clinical Trial, Open, Parallel Groups , Value the Antiproteinuric Effects From Vitamin D Derivatives in Patient With Chronic Kidney Illness and the Lack of Vitamin D Unknown status NCT01442272 Phase 4 Hidroferol®;Paricalcitol: Zemplar®;Habitual medication
30 The Determinants of the Effectiveness of the Use of Furosemide in Patients on Dialysis Unknown status NCT01815892 Phase 4 Withdrawal of furosemide;furosemide administration
31 Upstream Use of Aliskiren in Hypertensive Haemodialysis Patients: Effects on Cardiovascular Outcomes Unknown status NCT01635387 Phase 4 aliskiren
32 Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease:a Multicentre Open Study Unknown status NCT02231138 Phase 4 Abelmoschus manihot (AM)
33 Effect of Vitamin D Supplement on Osteoprotegin Expression and Disease Progression in Patients With Chronic Kidney Disease Stage 1 and 2 Unknown status NCT01561222 Phase 4 Calcitriol;placebo
34 Effect of Aliskiren on Muscle Sympathetic Nerve Activity (MSNA) in Hypertensive Patients With Chronic Kidney Disease Unknown status NCT00719316 Phase 4 Aliskiren
35 Efficacy and Safety of Morning Intake of Simvast Controlled Release (CR) Tablet Versus Evening Intake of Zocor Tablet in Chronic Kidney Disease Stage(CKD)3, 4 and 5 Patients With Hyperlipidemia: A Randomized, Double-blind, Multicenter Phase 4 Trial (HM-SIM4) Unknown status NCT01564875 Phase 4 Simvast CR;Zocor
36 Canadian Collaborative Group for the Prevention of Illness in Chronic Renal Disease. The Canadian Prevention of Renal and Cardiovascular Endpoints Trial Unknown status NCT00231803 Phase 4
37 The Immunogenicity and Safety of the Seasonal Influenza Vaccine, Formulation 2013-2014, in Chronic Kidney Disease Patients Not on Dialysis Unknown status NCT02105519 Phase 4
38 Comparison of the Effects Between Keto-/Amino Acid Supplemented Low Protein Diet and Non-Supplemented Low Protein Diet in Patients With Stage Ⅴ Chronic Kidney Disease Unknown status NCT00364884 Phase 4 ketoaminoacid
39 The Association Between Body Composition and Biomarkers in Hemodialysis Patients Unknown status NCT01103167 Phase 4
40 Protective Mechanisms of Aldosterone Antagonists and Their Effects on Cardiovascular Damage in Chronic Renal Failure: Clinical and Experimental Studies Unknown status NCT00277693 Phase 4 Spironolactone (drug)
41 Comparison of Efficacy and Safety Between Benidipine and Hydrochlorothiazide in Fosinopril Treated Chronic Kidney Disease Patients With Hypertension: a Randomized Controlled Trial Unknown status NCT02646397 Phase 4 Fosinopril;Benidipine;Hydrochlorothiazide
42 The Change of Urinary Angiotensinogen Excretion After Valsartan Treatment in Chronic Kidney Diseases Patients With Persistent Proteinuria Unknown status NCT00858299 Phase 4 valsartan
43 Additive Renoprotective Effects of Oral Calcitriol in Nondiabetic Chronic Kidney Disease Patients Unknown status NCT01512862 Phase 4 Calcitriol;Placebo
44 Phase 4 Study of Oral Calcitriol for Reduction of Mild Proteinuria in Patients With CKD Unknown status NCT01820832 Phase 4 Calcitriol
45 Interstitial Fibrosis in Protocol Biopsies of Renal Allografts: A Prospective, Randomised Trial of Sirolimus Versus Cyclosporine.(Fibrasic) Unknown status NCT00493194 Phase 4 sirolimus;cyclosporine;daclizumab
46 A Prospective Randomized, Double-Blind Parallel Group Trial To Assess The Efficacy And Safety Of Intravenous Dextrose 5% Solution Compare With Normal Saline (Standard Care) In Rinsing During Haemodialysis In Subjects With End Stage Renal Failure (ESRF) With Respect To Systolic Blood Pressure Control Over 3 Months Period. Unknown status NCT02590081 Phase 4 Dextrose 5%;normal saline
47 Effects of On-Line Hemodiafiltration(HDF) on Endothelial Dysfunction in Chronic Hemodialysis Patients Unknown status NCT00532597 Phase 4
48 A Randomized Prospective Trial of N-acetyl Cystein in Patients With Peritoneal Dialysis Unknown status NCT01111422 Phase 4 N-acetylcysteine
49 Effect of Ursodeoxycholic Acid on Peritoneal Function in Patients on Peritoneal Dialysis Unknown status NCT02338635 Phase 4 Ursodeoxycholic Acid
50 Pragmatic Randomized Controlled Trial Comparing Treatment Effectiveness of Guideline Indicated Anti-platelet Therapy for Acute Coronary Syndrome in Patients With Chronic Kidney Disease Unknown status NCT03150667 Phase 4 Ticagrelor;Clopidogrel

Search NIH Clinical Center for Chronic Kidney Disease

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Chronic Kidney Disease cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: kidney failure, chronic

Genetic Tests for Chronic Kidney Disease

Genetic tests related to Chronic Kidney Disease:

# Genetic test Affiliating Genes
1 Chronic Kidney Disease 29

Anatomical Context for Chronic Kidney Disease

MalaCards organs/tissues related to Chronic Kidney Disease:

40
Kidney, Bone, Heart, Endothelial, Liver, Testes, Neutrophil
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Chronic Kidney Disease:
# Tissue Anatomical CompartmentCell Relevance
1 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate
2 Adipose Subcutaneous White Adipose Mesenchymal Stem Cells Potential therapeutic candidate
3 Kidney Proximal Tubule Proximal Tubule Cells Affected by disease, potential therapeutic candidate
4 Adipose Subcutaneous White Adipose Stromal Cells Potential therapeutic candidate

Publications for Chronic Kidney Disease

Articles related to Chronic Kidney Disease:

(show top 50) (show all 34335)
# Title Authors PMID Year
1
Clinical trial for conventional medicine integrated with traditional Chinese medicine (TCM) in the treatment of patients with chronic kidney disease. 61 42
32481298 2020
2
Effect of statins on cardiovascular complications in chronic kidney disease patients: A network meta-analysis. 42 61
32481375 2020
3
Risk of carpal tunnel syndrome after parathyroidectomy in patients with end-stage renal disease: A population-based cohort study in Taiwan. 42
32443382 2020
4
A prospective study of fibroblast growth factor-23 in children with chronic kidney disease. 61 54
19929273 2010
5
Insulin resistance as a novel therapeutic target in patients with chronic kidney disease treated with dialysis. 61 54
20150846 2010
6
Role of aldosterone in the progression of chronic kidney disease and potential use of aldosterone blockade in children. 61 54
19347366 2009
7
Inflammatory syndrome in chronic kidney disease: pathogenesis and influence on outcomes. 61 54
20025585 2009
8
[BNP and echocardiographic parameters in patients with chronic kidney disease and dialyzed patients]. 54 61
19947237 2009
9
Inflammation in chronic kidney disease: role in the progression of renal and cardiovascular disease. 61 54
19083024 2009
10
Outcome predictability of biomarkers of protein-energy wasting and inflammation in moderate and advanced chronic kidney disease. 61 54
19535427 2009
11
Impact of left ventricular end-diastolic wall stress on plasma B-type natriuretic peptide in heart failure with chronic kidney disease and end-stage renal disease. 61 54
19460838 2009
12
Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease. 54 61
19138652 2009
13
Insulin resistance in chronic uremia. 61 54
19121765 2009
14
New acquisitions in therapy of secondary hyperparathyroidism in chronic kidney disease and peritoneal dialysis patients: role of vitamin D receptor activators. 61 54
19494617 2009
15
[Insulin resistance and chronic kidney disease]. 54 61
18514051 2008
16
Vitamin D: an old prohormone with an emergent role in chronic kidney disease. 61 54
18587719 2008
17
[Peritoneal dialysis and insulin resistance in patients with chronic kidney disease due to nondiabetic nephropathy]. 61 54
18634374 2008
18
Management of hyperglycemia in patients with diabetes mellitus and chronic renal failure. 54 61
18923754 2008
19
Adiponectin and chronic kidney disease. 61 54
17198925 2007
20
Association between vitamin D receptor gene polymorphisms and susceptibility to chronic kidney disease and periodontitis. 61 54
17914260 2007
21
Stature in children with chronic kidney disease: analysis of NAPRTCS database. 54 61
16583244 2006
22
Arginine, arginine analogs and nitric oxide production in chronic kidney disease. 61 54
16932427 2006
23
FGF-23 and sFRP-4 in chronic kidney disease and post-renal transplantation. 61 54
16691036 2006
24
Progressive loss of renal function is associated with activation and depletion of naive T lymphocytes. 61 54
16257266 2006
25
Biomarkers in chronic kidney disease: utility and issues towards better understanding. 61 54
16205471 2005
26
[Early diagnosis of chronic kidney diseases]. 54 61
15742164 2005
27
Adiponectin in chronic kidney disease is related more to metabolic disturbances than to decline in renal function. 54 61
15585515 2005
28
Association of TGF-beta1 polymorphisms with chronic renal disease. 54 61
15593053 2004
29
Potential cardiovascular risk factors in chronic kidney disease: AGEs, total homocysteine and metabolites, and the C-reactive protein. 61 54
15200442 2004
30
[Biological activity of FGF-23 and pathophysiologic role in chronic kidney disease]. 61 54
15577039 2004
31
Roles of oxidative stress and antioxidant therapy in chronic kidney disease and hypertension. 54 61
15090865 2004
32
Vascular calcification in chronic kidney disease. 61 54
14730511 2004
33
Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. 61 54
14633152 2003
34
Leptin, ghrelin, and proinflammatory cytokines: compounds with nutritional impact in chronic kidney disease? 54 61
14681862 2003
35
Effects of short-term recombinant human growth hormone therapy on plasma leptin concentrations in dialysis patients. 61 54
11812876 2002
36
Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. 61 54
11453706 2001
37
Urinary excretion of vasoactive substances in chronic renal failure. 61 54
11393385 2001
38
Serum hepatocyte growth factor levels in patients with chronic renal disease--effect of GFR and pathogenesis. 54 61
11768321 2001
39
Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: a systematic overview of randomized placebo-controlled trials. 61 54
10739792 2000
40
Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. 54 61
10219067 1999
41
The effect of metabolic acidosis on serum apolipoprotein A I and apolipoprotein B levels in children with chronic renal failure. 61 54
9413770 1997
42
Endothelial function and the kidney. An emerging target for cardiovascular therapy. 54 61
9034751 1997
43
Role of lipid peroxidation, trace elements and anti-oxidant enzymes in chronic renal disease patients. 54 61
9071084 1996
44
The changes in serum type I and III procollagen, insulin-like growth factor-I and insulin-like growth factor binding protein-3 levels in children with chronic renal failure. 61 54
8936957 1996
45
Long-term impact of recombinant human erythropoietin on transfusion support in patients with chronic renal failure. 54 61
15387752 1996
46
Fluvastatin for dyslipoproteinemia, with or without concomitant chronic renal insufficiency. 54 61
7604809 1995
47
Insulin and growth in chronic renal failure. 61 54
7917856 1994
48
A granulocyte inhibitory protein overexpressed in chronic renal disease regulates expression of interleukin 6 and interleukin 8. 61 54
8278382 1994
49
Effects of atrial natriuretic peptide (99-126) in chronic renal disease in man. 54 61
1831249 1991
50
Serum leptin levels are positively associated with aortic stiffness in patients with chronic kidney disease stage 3-5. 61
32403968 2020

Variations for Chronic Kidney Disease

ClinVar genetic disease variations for Chronic Kidney Disease:

6 (show all 47) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 COL4A4 NM_000092.5(COL4A4):c.2906C>GSNV Pathogenic 449549 rs35138315 2:227917083-227917083 2:227052367-227052367
2 COL4A5 NM_033380.3(COL4A5):c.3614G>T (p.Gly1205Val)SNV Pathogenic 523547 rs1556446493 X:107911558-107911558 X:108668328-108668328
3 COL4A4 NM_000092.5(COL4A4):c.4603_4604del (p.Gln1535fs)deletion Pathogenic 915852 2:227872939-227872940 2:227008223-227008224
4 PKD2 NM_000297.4(PKD2):c.357_364delinsTAGGACG (p.Pro120fs)indel Pathogenic 373955 rs1057518797 4:88929242-88929249 4:88008090-88008097
5 AXDND1 , NPHS2 NM_144696.6(AXDND1):c.3032-1891_3032-1890deldeletion Pathogenic/Likely pathogenic 188823 rs749740335 1:179521755-179521756 1:179552620-179552621
6 MKS1 NM_001165927.1(MKS1):c.1085_1087del (p.Ser362del)deletion Pathogenic/Likely pathogenic 217677 rs754279998 17:56285514-56285516 17:58208153-58208155
7 SLC13A5 NM_177550.4(SLC13A5):c.231+2T>GSNV Likely pathogenic 183313 rs730882222 17:6610345-6610345 17:6707026-6707026
8 NPHS2 NM_014625.3(NPHS2):c.413G>A (p.Arg138Gln)SNV Conflicting interpretations of pathogenicity 5360 rs74315342 1:179530462-179530462 1:179561327-179561327
9 UMOD NM_003361.4(UMOD):c.1243C>T (p.Arg415Cys)SNV Conflicting interpretations of pathogenicity 884577 16:20355434-20355434 16:20344112-20344112
10 CFH NM_000186.4(CFH):c.2517C>ASNV Conflicting interpretations of pathogenicity 591005 rs1362306576 1:196706057-196706057 1:196736927-196736927
11 APOA1 NM_000039.2(APOA1):c.388_390AAG[1] (p.Lys131del)short repeat Conflicting interpretations of pathogenicity 636899 11:116706935-116706937 11:116836219-116836221
12 COL4A3 NM_000091.5(COL4A3):c.1886C>TSNV Conflicting interpretations of pathogenicity 452348 rs139361545 2:228137792-228137792 2:227273076-227273076
13 CFHR5 NM_030787.4(CFHR5):c.486dup (p.Glu163fs)duplication Conflicting interpretations of pathogenicity 402534 rs565457964 1:196963258-196963259 1:196994128-196994129
14 PKD1 NM_001009944.3(PKD1):c.9898G>A (p.Gly3300Arg)SNV Conflicting interpretations of pathogenicity 427112 rs777024498 16:2149887-2149887 16:2099886-2099886
15 EHHADH NM_001966.4(EHHADH):c.2108C>T (p.Ser703Phe)SNV Conflicting interpretations of pathogenicity 774610 3:184910078-184910078 3:185192290-185192290
16 FN1 NM_212482.3(FN1):c.4486C>T (p.Arg1496Trp)SNV Conflicting interpretations of pathogenicity 779411 2:216251538-216251538 2:215386815-215386815
17 FN1 NM_212482.3(FN1):c.1775G>A (p.Arg592His)SNV Conflicting interpretations of pathogenicity 790514 2:216284009-216284009 2:215419286-215419286
18 FN1 NM_212482.3(FN1):c.1070G>A (p.Gly357Glu)SNV Conflicting interpretations of pathogenicity 791471 2:216289015-216289015 2:215424292-215424292
19 GANAB NM_198334.3(GANAB):c.925C>T (p.Arg309Cys)SNV Conflicting interpretations of pathogenicity 716421 11:62400108-62400108 11:62632636-62632636
20 FN1 NM_212482.3(FN1):c.5954C>A (p.Pro1985His)SNV Conflicting interpretations of pathogenicity 721814 2:216240375-216240375 2:215375652-215375652
21 INF2 NM_022489.4(INF2):c.3221G>A (p.Arg1074Lys)SNV Conflicting interpretations of pathogenicity 245863 rs201445955 14:105180720-105180720 14:104714383-104714383
22 CFHR5 NM_030787.3(CFHR5):c.622T>C (p.Cys208Arg)SNV Conflicting interpretations of pathogenicity 279752 rs41299613 1:196964861-196964861 1:196995731-196995731
23 TTC21B NM_024753.5(TTC21B):c.3004C>G (p.Leu1002Val)SNV Conflicting interpretations of pathogenicity 195777 rs146496725 2:166747445-166747445 2:165890935-165890935
24 COL4A1 NM_001845.6(COL4A1):c.161C>T (p.Pro54Leu)SNV Conflicting interpretations of pathogenicity 196327 rs34004222 13:110866346-110866346 13:110213999-110213999
25 ETFB NM_001985.3(ETFB):c.292C>T (p.Arg98Cys)SNV Conflicting interpretations of pathogenicity 203697 rs147353781 19:51856469-51856469 19:51353215-51353215
26 FREM1 NM_144966.5(FREM1):c.1640C>G (p.Ala547Gly)SNV Uncertain significance 366157 rs201056172 9:14842412-14842412 9:14842414-14842414
27 PKD1 NM_001009944.3(PKD1):c.12460C>T (p.Arg4154Cys)SNV Uncertain significance 803159 16:2140180-2140180 16:2090179-2090179
28 COL4A3 NM_000091.5(COL4A3):c.4700T>G (p.Ile1567Ser)SNV Uncertain significance 829912 2:228173979-228173979 2:227309263-227309263
29 ZNF423 NM_001271620.2(ZNF423):c.2071C>T (p.Arg691Cys)SNV Uncertain significance 645949 16:49670812-49670812 16:49636901-49636901
30 TBX18 NM_001080508.3(TBX18):c.574G>T (p.Val192Leu)SNV Uncertain significance 915854 6:85469998-85469998 6:84760280-84760280
31 ANLN NM_018685.5(ANLN):c.575C>G (p.Ser192Trp)SNV Uncertain significance 915855 7:36445877-36445877 7:36406268-36406268
32 DSTYK NM_015375.3(DSTYK):c.2776G>T (p.Asp926Tyr)SNV Uncertain significance 915849 1:205116700-205116700 1:205147572-205147572
33 CEL NM_001807.5(CEL):c.1966G>C (p.Ala656Pro)SNV Uncertain significance 128688 rs587780309 9:135946855-135946855 9:133071468-133071468
34 EHHADH NC_000003.12:g.185204731_185204732AG[1]short repeat Uncertain significance 915857 3:184922519-184922520 3:185204731-185204732
35 SOX17 NC_000008.11:g.54459704_54459709GCACCA[5]short repeat Uncertain significance 915867 8:55372258-55372259 8:54459698-54459699
36 APOA1 NM_000039.3(APOA1):c.625G>A (p.Gly209Ser)SNV Uncertain significance 915860 11:116706703-116706703 11:116835987-116835987
37 WT1 NM_024426.6(WT1):c.576G>T (p.Gln192His)SNV Uncertain significance 915856 11:32456331-32456331 11:32434785-32434785
38 ARHGDIA NM_004309.6(ARHGDIA):c.*243G>ASNV Uncertain significance 915863 17:79826509-79826509 17:81868633-81868633
39 ACTN4 NM_004924.6(ACTN4):c.928C>T (p.Arg310Trp)SNV Uncertain significance 915866 19:39207741-39207741 19:38717101-38717101
40 CFHR1 NM_002113.3(CFHR1):c.911A>GSNV Uncertain significance 915865 1:196801047-196801047 1:196831917-196831917
41 CFHR1 NM_002113.3(CFHR1):c.727C>GSNV Uncertain significance 915861 1:196799749-196799749 1:196830619-196830619
42 FN1 NM_212482.4(FN1):c.3130G>ASNV Uncertain significance 915850 2:216269235-216269235 2:215404512-215404512
43 FN1 NM_212482.4(FN1):c.7408G>CSNV Uncertain significance 915862 2:216226304-216226304 2:215361581-215361581
44 CFHR1 NM_002113.3(CFHR1):c.790+1G>ASNV Uncertain significance 915864 1:196799813-196799813 1:196830683-196830683
45 SLC9A3R1 NM_004252.5(SLC9A3R1):c.458G>A (p.Arg153Gln)SNV Uncertain significance 5271 rs41282065 17:72758167-72758167 17:74762028-74762028
46 CFI NM_000204.4(CFI):c.782G>A (p.Gly261Asp)SNV Likely benign 65580 rs112534524 4:110681527-110681527 4:109760371-109760371
47 COL4A3 NM_000091.4(COL4A3):c.346C>A (p.Pro116Thr)SNV Benign/Likely benign 254994 rs115324397 2:228110691-228110691 2:227245975-227245975

Expression for Chronic Kidney Disease

Search GEO for disease gene expression data for Chronic Kidney Disease.

Pathways for Chronic Kidney Disease

GO Terms for Chronic Kidney Disease

Cellular components related to Chronic Kidney Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10